| 1 |
34791836 | Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial. | 2022 Jan |
1 |
| 2 |
35591835 | Ibrutinib attenuated DSS-induced ulcerative colitis, oxidative stress, and the inflammatory cascade by modulating the PI3K/Akt and JNK/NF-κB pathways. | 2022 |
1 |
| 3 |
32381576 | Novel pyrrolobenzodiazepine benzofused hybrid molecules inhibit NF-κB activity and synergise with bortezomib and ibrutinib in hematological cancers. | 2021 Apr 1 |
1 |
| 4 |
34474146 | miRNA-223-3p modulates ibrutinib resistance through regulation of the CHUK/Nf-κb signaling pathway in mantle cell lymphoma. | 2021 Nov |
3 |
| 5 |
31811349 | The protective effect of Geniposide on diabetic cognitive impairment through BTK/TLR4/NF-κB pathway. | 2020 Feb |
1 |
| 6 |
32228672 | Inhibition of effector B cells by ibrutinib in systemic sclerosis. | 2020 Mar 30 |
1 |
| 7 |
33067379 | Effect of Ibrutinib on the IFN Response of Chronic Lymphocytic Leukemia Cells. | 2020 Nov 15 |
1 |
| 8 |
30510142 | XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of IκB. | 2018 Dec |
3 |
| 9 |
26099967 | The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells. | 2015 Aug |
1 |
| 10 |
24362935 | Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphoma. | 2014 Jan |
2 |
| 11 |
24659631 | Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL. | 2014 May 22 |
1 |